A COMPETITIVE CHROMOGENIC ASSAY TO STUDY THE FUNCTIONAL INTERACTION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR WITH ITS RECEPTOR

被引:15
作者
RETTENBERGER, P
WILHELM, O
OI, H
WEIDLE, UH
GORETZKI, L
KOPPITZ, M
LOTTSPEICH, F
KONIG, B
PESSARA, U
KRAMER, MD
SCHMITT, M
MAGDOLEN, V
机构
[1] TECH UNIV MUNICH,FRAUENKLIN,D-81675 MUNICH,GERMANY
[2] BOEHRINGER MANNHEIM GMBH,D-82377 PENZBERG,GERMANY
[3] TECH UNIV MUNICH,INST ORGAN CHEM & BIOCHEM,D-85748 GARCHING,GERMANY
[4] MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY
[5] UNIV HEIDELBERG,INST IMMUNOL,D-69120 HEIDELBERG,GERMANY
来源
BIOLOGICAL CHEMISTRY HOPPE-SEYLER | 1995年 / 376卷 / 10期
关键词
HETEROLOGOUS EXPRESSION; RECEPTOR; TUMOR INVASION; UPA;
D O I
10.1515/bchm3.1995.376.10.587
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urokinase-type plasminogen activator (uPA) converts plasminogen to plasmin which degrades various extracellular matrix components. uPA is focused to the cell surface via binding to a specific receptor (uPAR, also termed CD87). uPAR-bound uPA mediates pericellular proteolysis in a variety of biological processes, e.g. cell migration, tissue remodeling and tumor invasion. We have developed a competitive microtiter plate-based chromogenic assay which allows the analysis of uPA/uPAR interaction. The plates are coated with recombinant uPAR expressed in Chinese hamster ovary (CHO) cells. Proteolytically active uPA (HMW-uPA) is added to the microtiter plate-attached uPAR. The amount of receptor-bound uPA is then determined indirectly via addition of plasminogen, which is activated to plasmin, followed by cleavage of a plasmin-specific chromogenic substrate. Substances interfering with binding of HMW-uPA to uPAR diminish the generation of plasmin, as indicated by a reduction of cleaved chromogenic substrate. This assay was used to analyze the inhibitory capacity of a variety of proteins and peptides, respectively, on the uPA/uPAR interaction: i) uPAR and uPAR-variants expressed in CHO cells, yeast or E. coli, ii) the aminoterminal fragment (ATF) of human uPA or yeast recombinant pro-uPA, iii) synthetic peptides derived from the sequence of the uPAR-binding region of uPA, and iv) antibodies directed against uPAR. This assay may be helpful in identifying uPA and uPAR analogues or antagonists which efficiently block uPA/uPAR interaction.
引用
收藏
页码:587 / 594
页数:8
相关论文
共 30 条
[21]   TUMOR-ASSOCIATED UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - BIOLOGICAL AND CLINICAL-SIGNIFICANCE [J].
SCHMITT, M ;
JANICKE, F ;
MONIWA, N ;
CHUCHOLOWSKI, N ;
PACHE, L ;
GRAEFF, H .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1992, 373 (07) :611-622
[22]  
Schmitt M, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P151
[23]  
Sherman F., 1986, METHODS YEAST GENETI
[24]   THE UROKINASE RECEPTOR [J].
VASSALLI, JD .
FIBRINOLYSIS, 1994, 8 :172-181
[25]   A FAMILY OF YEAST EXPRESSION VECTORS CONTAINING THE PHAGE-F1 INTERGENIC REGION [J].
VERNET, T ;
DIGNARD, D ;
THOMAS, DY .
GENE, 1987, 52 (2-3) :225-233
[26]   EXPRESSION OF FUNCTIONAL PAPAIN PRECURSOR IN SACCHAROMYCES-CEREVISIAE - RAPID SCREENING OF MUTANTS [J].
VERNET, T ;
CHATELLIER, J ;
TESSIER, DC ;
THOMAS, DY .
PROTEIN ENGINEERING, 1993, 6 (02) :213-219
[27]   ANTISENSE INHIBITION OF UROKINASE REDUCES SPREAD OF HUMAN OVARIAN-CANCER IN MICE [J].
WILHELM, O ;
SCHMITT, M ;
HOHL, S ;
SENEKOWITSCH, R ;
GRAEFF, H .
CLINICAL & EXPERIMENTAL METASTASIS, 1995, 13 (04) :296-302
[28]   RECOMBINANT SOLUBLE UROKINASE RECEPTOR AS A SCAVENGER FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) - INHIBITION OF PROLIFERATION AND INVASION OF HUMAN OVARIAN-CANCER CELLS [J].
WILHELM, O ;
WEIDLE, U ;
HOHL, S ;
RETTENBERGER, P ;
SCHMITT, M ;
GRAEFF, H .
FEBS LETTERS, 1994, 337 (02) :131-134
[29]  
WILHELM O, 1994, EXCERPTA MED, V1050, P145
[30]  
WILHELM OG, 1990, J BIOL CHEM, V265, P14606